Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

C-reactive protein is essential for innate resistance to pneumococcal infection.

Simons JP, Loeffler JM, Al-Shawi R, Ellmerich S, Hutchinson WL, Tennent GA, Petrie A, Raynes JG, de Souza JB, Lawrence RA, Read KD, Pepys MB.

Immunology. 2014 Jul;142(3):414-20. doi: 10.1111/imm.12266.

2.

Pathogenetic mechanisms of amyloid A amyloidosis.

Simons JP, Al-Shawi R, Ellmerich S, Speck I, Aslam S, Hutchinson WL, Mangione PP, Disterer P, Gilbertson JA, Hunt T, Millar DJ, Minogue S, Bodin K, Pepys MB, Hawkins PN.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16115-20. doi: 10.1073/pnas.1306621110. Epub 2013 Aug 19.

3.

Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.

Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, Ellmerich S, Mangione PP, Tennent GA, Hutchinson WL, Millar DJ, Bennett G, More J, Evans D, Mistry Y, Poole S, Hawkins PN.

J Immunol Methods. 2012 Oct 31;384(1-2):92-102. doi: 10.1016/j.jim.2012.07.013. Epub 2012 Jul 31.

4.

Immunoradiometric assay for human serum amyloid P component.

Millar DJ, Hutchinson WL, Pepys MB.

J Immunol Methods. 2011 Aug 31;371(1-2):18-24. doi: 10.1016/j.jim.2011.06.010. Epub 2011 Jun 25.

PMID:
21708157
5.

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB.

Nature. 2010 Nov 4;468(7320):93-7. doi: 10.1038/nature09494. Epub 2010 Oct 20.

6.

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.

Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB.

Br J Haematol. 2010 Mar;148(5):760-7. doi: 10.1111/j.1365-2141.2009.08036.x. Epub 2010 Jan 8.

PMID:
20064157
7.

Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23. doi: 10.1073/pnas.0902640106. Epub 2009 Apr 16.

8.

Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice.

Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB.

Atherosclerosis. 2008 Jan;196(1):248-55. Epub 2007 Jun 22.

PMID:
17588586
9.

Is leptin an important physiological regulator of CRP?

Hutchinson WL, Coll AP, Gallimore JR, Tennent GA, Pepys MB.

Nat Med. 2007 Jan;13(1):17-8; author reply 19-21. No abstract available.

PMID:
17206123
10.

Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.

Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8309-14. Epub 2005 May 26.

11.

Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?

Gillmore JD, Hutchinson WL, Herbert J, Bybee A, Mitchell DA, Hasserjian RP, Yamamura K, Suzuki M, Sabin CA, Pepys MB.

Immunology. 2004 Jun;112(2):255-64.

12.
13.

Determination of C-reactive protein: comparison of three high-sensitivity immunoassays.

Khuseyinova N, Imhof A, Trischler G, Rothenbacher D, Hutchinson WL, Pepys MB, Koenig W.

Clin Chem. 2003 Oct;49(10):1691-5. No abstract available.

14.
15.

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.

Nature. 2002 May 16;417(6886):254-9.

PMID:
12015594
16.

Influenza virus infection is not affected by serum amyloid P component.

Herbert J, Hutchinson WL, Carr J, Ives J, Jakob-Roetne R, Yamamura K, Suzuki M, Pepys MB.

Mol Med. 2002 Jan;8(1):9-15.

17.

Lack of seasonal variation in C-reactive protein.

Fröhlich M, Sund M, Thorand B, Hutchinson WL, Pepys MB, Koenig W.

Clin Chem. 2002 Mar;48(3):575-7. No abstract available.

18.

Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study.

Peters A, Fröhlich M, Döring A, Immervoll T, Wichmann HE, Hutchinson WL, Pepys MB, Koenig W.

Eur Heart J. 2001 Jul;22(14):1198-204.

PMID:
11440492
19.

Association between C-reactive protein and features of the metabolic syndrome: a population-based study.

Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W.

Diabetes Care. 2000 Dec;23(12):1835-9.

20.

Human serum amyloid P component is a single uncomplexed pentamer in whole serum.

Hutchinson WL, Hohenester E, Pepys MB.

Mol Med. 2000 Jun;6(6):482-93.

21.

Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population.

Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB.

Clin Chem. 2000 Jul;46(7):934-8.

22.

C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.

Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB.

J Exp Med. 1999 Dec 20;190(12):1733-40.

23.

Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity.

Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, Mitchell DA, Cook HT, Butler PJ, Walport MJ, Pepys MB.

Nat Med. 1999 Jun;5(6):694-7.

PMID:
10371509
25.

Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene.

Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB.

Nat Med. 1997 Aug;3(8):855-9.

PMID:
9256275
26.

Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP.

Hohenester E, Hutchinson WL, Pepys MB, Wood SP.

J Mol Biol. 1997 Jun 20;269(4):570-8.

PMID:
9217261
27.

Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis.

Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CC, Pepys MB.

Nature. 1997 Feb 27;385(6619):787-93.

PMID:
9039909
28.

Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.

Booth DR, Tan SY, Booth SE, Tennent GA, Hutchinson WL, Hsuan JJ, Totty NF, Truong O, Soutar AK, Hawkins PN, Bruguera M, Caballería J, Solé M, Campistol JM, Pepys MB.

J Clin Invest. 1996 Jun 15;97(12):2714-21.

29.

Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.

Pepys MB, Tennent GA, Booth DR, Bellotti V, Lovat LB, Tan SY, Persey MR, Hutchinson WL, Booth SE, Madhoo S, Soutar AK, Hawkins PN, Van Zyl-Smit R, Campistol JM, Fraser PE, Radford SE, Robinson CV, Sunde M, Serpell LC, Blake CC.

Ciba Found Symp. 1996;199:73-81; discussion 81-9.

PMID:
8915605
30.

A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis.

Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T, Vigushin DM, Tennent GA, Hutchinson WL, et al.

QJM. 1995 Oct;88(10):695-702. Review.

PMID:
7493166
31.
32.

Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, et al.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5602-6.

33.

Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma.

Hutchinson WL, Johnson PJ, Du MQ, Williams R.

Clin Sci (Lond). 1991 Aug;81(2):177-82.

PMID:
1716188
34.

Impaired binding properties of thyroxine-binding globulin in hepatocellular carcinoma and chronic liver disease.

Hutchinson WL, White YS, Fagan EA, Johnson PJ, Williams R.

Hepatology. 1991 Jul;14(1):116-20.

PMID:
1648537
35.

Substantial quantities of the high energy derivative oligophosphoglyceroyl-ATP are located in mitochondria in rat liver.

Patel B, Gove CD, Hutchinson WL, Mowbray J.

Biochim Biophys Acta. 1991 May 24;1074(1):178-81.

PMID:
2043668
36.

Fucosyltransferases: differential plasma and tissue alterations in hepatocellular carcinoma and cirrhosis.

Hutchinson WL, Du MQ, Johnson PJ, Williams R.

Hepatology. 1991 Apr;13(4):683-8.

PMID:
1849114
37.

Differential alpha-fetoprotein lectin binding in hepatocellular carcinoma. Diagnostic utility at low serum levels.

Du MQ, Hutchinson WL, Johnson PJ, Williams R.

Cancer. 1991 Jan 15;67(2):476-80.

PMID:
1702350
38.

Altered plasma and tissue fucosyltransferase activities in hepatocellular carcinoma.

Du MQ, Hutchinson WL, Johnson PJ, Williams R.

Biochem Soc Trans. 1990 Jun;18(3):489. No abstract available.

PMID:
2165000
39.
40.

Differential hormone-binding characteristics of thyroxine-binding globulin in hepatocellular carcinoma and cirrhosis.

Hutchinson WL, Johnson PJ, White YS, Williams R.

J Hepatol. 1989 Sep;9(2):265-71.

PMID:
2553799
41.

A comparison of rapid adenine nucleotide incorporation into phosphoglyceroyl-ATP and into RNA-like species in perfused rat heart.

Heyworth PG, Hutchinson WL, Mowbray J.

Biochim Biophys Acta. 1987 Feb 18;927(2):158-62.

PMID:
2434135
42.

Evidence for the presence of oligophosphoglyceroyl-ATP in rat offney.

Hutchinson WL, Ratcliffe PJ, Mowbray J.

Biochem J. 1986 Dec 1;240(2):597-9.

43.
44.

The discovery of a rapidly metabolized polymeric tetraphosphate derivative of adenosine in perfused rat heart.

Mowbray J, Hutchinson WL, Tibbs GR, Morris PG.

Biochem J. 1984 Nov 1;223(3):627-32.

Supplemental Content

Loading ...
Support Center